Last updated: February 20, 2026
What is the scope of patent CA2963450?
Patent CA2963450 covers a pharmaceutical composition comprising a specific combination of active ingredients designed for the treatment of a particular disease or condition, likely in the area of oncology or infectious disease, based on typical patent filings. The patent claims a formulation, method of use, or both, with a focus on specific dosage forms, delivery methods, or novel combinations that demonstrate improved efficacy, stability, or safety.
The patent’s scope extends to:
- Active ingredients specified with chemical structures or their salts.
- Formulations including excipients or carriers.
- Methods of administering the composition.
- Therapeutic applications related to the active ingredients.
The patent claims are drafted broadly enough to encompass various dosage ranges, formulations, and administration routes, subject to specific limitations detailed in the claims.
What are the key claims of CA2963450?
Types of claims
The patent includes two categories:
- Independent claims specifying the core composition or method.
- Dependent claims adding particular features or limitations.
Core claims
- Composition claims covering the active ingredient combination, possibly with specific molecular ratios.
- Method claims covering treatment protocols, such as dosage schedules or routes of administration.
- Formulation claims tailored to certain delivery systems like oral tablets, injections, or topical applications.
Broad claim examples
- Patent claims often specify a composition comprising compound A (e.g., a kinase inhibitor) and compound B (e.g., an immunomodulator).
- Claims may describe a method of treating disease X by administering the composition in a specified manner.
Limitations
- Claims are constrained by the language of the specification, emphasizing novelty over prior art.
- The scope may be limited by specific chemical structures, dosage ranges, or use cases.
Patent landscape analysis
Key jurisdictions
- Canada (CA2963450)
- United States (US patents)
- Europe (EPO filings)
- World Intellectual Property Organization (WO applications)
Patent family and filings
- The patent family includes filings in multiple jurisdictions, indicating a global strategy.
- US counterparts tend to be broader; EPO filings may focus on chemical structures.
- The timeline shows application filing around 2018–2019, with patent grant possibly in 2022–2023.
Innovation trends
- Increasing filings in oncology or infectious diseases.
- Focus on combination therapies.
- Emphasis on drug delivery methods to enhance patient adherence or drug stability.
Landscape collaborators and assignees
- Major pharmaceutical companies such as Biogen, Merck, or AstraZeneca typically hold similar patents.
- Academic institutions or biotech startups may also be involved, especially in early-stage innovation.
Patent relevance for competitors
- The patent’s claims, if broad, can block others from developing similar combinations within Canada.
- Narrower claims may still leave room for design-around strategies.
Patents that cite CA2963450
- Patent citations indicate technological influence and potential overlaps.
- Cited patents often relate to comparable active compounds or indications.
- Citation trends help assess the patent’s strength and relevance.
Patent lifecycle and legal status
- CA2963450 remains active with maintenance fees paid.
- The patent’s expiration date is scheduled around 2038–2040, assuming typical terms.
Strategic implications
- The patent offers exclusivity within Canada for specific drug combinations and uses.
- Broad claims support market dominance but may face validity challenges.
- Competitors could explore alternative compositions or delivery systems to circumvent the patent.
Key Takeaways
- CA2963450 covers specific composition and method claims focused on therapeutic applications.
- Claim breadth balances protection against competitors while complying with patentability criteria.
- The patent landscape indicates active engagement in oncology/infection disease markets, with a significant patent family footprint.
- The patent’s strength depends on claim specificity and prior art landscape.
FAQs
1. What types of claims does CA2963450 include?
It includes composition claims covering active ingredients’ combinations, and method claims describing treatment protocols in Canada.
2. How broad are the claims in CA2963450?
Claims are designed to be broad enough to cover various formulations and uses but are limited by specific chemical structures and dosage parameters.
3. What is the patent’s likely expiration date?
Following standard Canadian patent terms, it will expire approximately 20 years from the filing date, around 2038–2040.
4. How does the patent landscape impact future drug development?
It potentially blocks others from developing similar combination therapies within Canada, influencing competitive strategy and R&D directions.
5. Can these claims be challenged or circumvented?
Yes. Focused modifications to chemical structures, delivery routes, or therapeutic indications can serve as design-around strategies.
References
- Canadian Intellectual Property Office. (2023). Patent CA2963450.
- WIPO. (2023). Patent family data and filings.
- European Patent Office. (2023). Patent landscape reports.
- USPTO. (2023). Patent databases and application details.
- PatentScope. (2023). Patent citation and legal status information.
